HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ramos-Suzarte, M. Articles by Pérez, R. Search for Related Content PubMed PubMed Citation Articles by Ramos-Suzarte, M. Articles by Pérez, R.

^99mTc-Labeled Antihuman Epidermal Growth Factor Receptor Antibody in Patients with Tumors of Epithelial Origin: Part III. Clinical Trials Safety and Diagnostic Efficacy

Center of Molecular Immunology, Center for Medical-Surgical Research, National Institute of Oncology and Radiobiology and Center of Clinical Researches, Havana, Cuba

Correspondence: For correspondence or reprints contact: Normando Iznaga-Escobar, MSc, Center of Molecular Immunology, PO Box 16040, Havana, 11600, Cuba.

ABSTRACT

Monoclonal antibody (moAb) ior egf/r3 is an IgG_2a that recognizes the epidermal growth factor receptor (EGF-R). The aim of this study was to evaluate the diagnostic efficacy of the ^99mTc-labeled moAb ior egf/r3 for the detection of epithelial-derived tumors, their metastases and recurrences. Methods: One hundred forty-eight adult patients (51 women, 97 men; mean age 53 ± 13 y) who were suspected of having cancer of epithelial origin were administered 3 mg/50 mCi (1.85 GBq) ^99mTc-labeled moAb ior egf/r3 by intravenous bolus injection. Planar anterior and posterior images of the lesion sites and suspected metastases were acquired at 2, 4, 6 and 24 h after injection, and SPECT images were scanned at 5 h postinjection, using a 360° circular orbit with 64 images. The backprojection method was used for image reconstruction with a Hamming-Hann filter. Results: Labeling efficiency was always greater than 98.5% ± 2.1%. No adverse reactions or side effects were observed. Results of the biopsy specimens showed that 85.1% (126/148) of the patients had tumors of epithelial origin, 14.2% (21/148) were negative and 0.7% (1/148) had non-Hodgkin's lymphoma. The sensitivity rate by organ was as follows: brain (8/8, 100%), digestive tract (10/11, 90.9%), head and neck (17/23, 73.9%), lung (52/62, 83.9%) and breast (16/18, 88.9%). Overall sensitivity, specificity, accuracy, and positive and negative predictive values of the immunoscintigraphic imaging were 84.2% (106/126), 100.0% (22/22), 86.5% (128/148), 100% (106/106) and 52.4% (22/42), respectively. New metastases not identified previously by other diagnostic methods were detected in the 50% of the patients. Conclusion: Immunoscintigraphy with ^99mTc-labeled moAb ior egf/r3 could be a useful procedure for the diagnosis and follow-up of the patients with tumors of epithelial origin.

Key Words: anti-epidermal growth factor receptor antibody • radioimmunoscintigraphy • diagnostic efficacy • epithelial tumors

This article has been cited by other articles:

				D. A. Mankoff, J. M. Link, H. M. Linden, L. Sundararajan, and K. A. Krohn Tumor Receptor Imaging J. Nucl. Med., June 1, 2008; 49(Suppl_2): 149S - 163S. [Abstract] [Full Text] [PDF]

				B. Van Den Bossche and C. Van de Wiele Receptor Imaging in Oncology by Means of Nuclear Medicine: Current Status J. Clin. Oncol., September 1, 2004; 22(17): 3593 - 3607. [Abstract] [Full Text] [PDF]